KRAS and malignant germ cell tumor: Malignant germ cell tumors have a low mutational burden, but the KIT, KRAS, TGF-BMP, and Wnt-catenin signaling pathway inhibitors and anti-CD30 immunotherapy can be used as targeted therapies in patients with resistant disease.